Sesen Bio, Inc. (SESN): Price and Financial Metrics
GET POWR RATINGS... FREE!
SESN POWR Grades
- Value is the dimension where SESN ranks best; there it ranks ahead of 62.5% of US stocks.
- The strongest trend for SESN is in Momentum, which has been heading down over the past 52 weeks.
- SESN's current lowest rank is in the Stability metric (where it is better than 1.43% of US stocks).
SESN Stock Summary
- For SESN, its debt to operating expenses ratio is greater than that reported by only 0.33% of US equities we're observing.
- The volatility of Sesen Bio Inc's share price is greater than that of 98.66% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SESN comes in at -92.8% -- higher than that of merely 2.74% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Sesen Bio Inc, a group of peers worth examining would be BB, SPOK, LMNL, RBBN, and LIVN.
- SESN's SEC filings can be seen here. And to visit Sesen Bio Inc's official web site, go to www.sesenbio.com.
SESN Valuation Summary
- In comparison to the median Healthcare stock, SESN's EV/EBIT ratio is 101.02% lower, now standing at -0.3.
- SESN's price/sales ratio has moved down 107.5 over the prior 92 months.
- Over the past 92 months, SESN's price/sales ratio has gone down 107.5.
Below are key valuation metrics over time for SESN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SESN | 2021-08-31 | 12.0 | 3.8 | -1.6 | -0.3 |
| SESN | 2021-08-30 | 11.6 | 3.7 | -1.5 | -0.3 |
| SESN | 2021-08-27 | 12.3 | 3.9 | -1.6 | -0.3 |
| SESN | 2021-08-26 | 12.6 | 4.0 | -1.7 | -0.4 |
| SESN | 2021-08-25 | 13.5 | 4.2 | -1.8 | -0.5 |
| SESN | 2021-08-24 | 13.2 | 4.2 | -1.7 | -0.5 |
SESN Growth Metrics
- The year over year net cashflow from operations growth rate now stands at -5.49%.
- Its 3 year net cashflow from operations growth rate is now at 23.59%.
- Its year over year cash and equivalents growth rate is now at 158.89%.
The table below shows SESN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 6.544 | -64.787 | -24.341 |
| 2021-06-30 | 17.78 | -54.127 | -118.571 |
| 2021-03-31 | 15.546 | -40.474 | -119.473 |
| 2020-12-31 | 11.236 | -30.837 | -22.544 |
| 2020-09-30 | 11.236 | -36.133 | -48.098 |
| 2020-06-30 | 0 | -39.104 | -38.622 |
SESN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SESN has a Quality Grade of C, ranking ahead of 52.29% of graded US stocks.
- SESN's asset turnover comes in at 0.094 -- ranking 266th of 682 Pharmaceutical Products stocks.
- SVRA, AUPH, and ONVO are the stocks whose asset turnover ratios are most correlated with SESN.
The table below shows SESN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.094 | 1 | 511.326 |
| 2021-03-31 | 0.120 | 1 | 31.068 |
| 2020-12-31 | 0.103 | 1 | 4.319 |
| 2020-09-30 | 0.105 | 1 | 14.394 |
| 2020-06-30 | 0.000 | NA | 7.880 |
| 2020-03-31 | 0.000 | NA | 13.068 |
SESN Price Target
For more insight on analysts targets of SESN, see our SESN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $2.25 | Average Broker Recommendation | 1.67 (Moderate Buy) |
SESN Stock Price Chart Interactive Chart >
SESN Price/Volume Stats
| Current price | $1.05 | 52-week high | $6.04 |
| Prev. close | $1.07 | 52-week low | $0.70 |
| Day low | $1.03 | Volume | 2,407,516 |
| Day high | $1.10 | Avg. volume | 12,460,764 |
| 50-day MA | $1.02 | Dividend yield | N/A |
| 200-day MA | $2.43 | Market Cap | 209.70M |
Sesen Bio, Inc. (SESN) Company Bio
Sesen Bio (formerly Eleven Biotherapeutics, Inc.), a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Latest SESN News From Around the Web
Below are the latest news stories about Sesen Bio Inc that investors may wish to consider to help them evaluate SESN as an investment opportunity.
Sesen Bio Strengthens Medical TeamCAMBRIDGE, Mass., November 29, 2021--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the strengthening of its medical team with the hiring of Dominika Kowalski as Senior Director of Global Drug Safety. Ms. Kowalski’s hiring demonstrates Sesen Bio’s strong commitment to and continued focus on the development of Vicineum™ for the treatment of BCG-unresponsive non-muscle invasive bladd |
Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor RoleCAMBRIDGE, Mass., November 23, 2021--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Jane Pritchett Henderson, previously a member of Sesen Bio’s Board of Directors and the Chair of the Board’s Audit Committee, has transitioned off the Board of Directors to a CEO Advisor role, effective November 22, 2021. Ms. Henderson departed the Board in order to concentrate on other respons |
Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022Sesen Bio, Inc. (SESN) suffered a setback in Q3 2021 after the US Food and Drug Administration (FDA) failed to approve its Biologics License Application (BLA) for Vicineum. The FDA questioned the current form of Vicineum as noted in the complete response letter ((CRL)). In addition, Sesen pulled out its... |
Sesen Bio (NASDAQ:SESN) investors are sitting on a loss of 52% if they invested five years agoSesen Bio, Inc. ( NASDAQ:SESN ) shareholders should be happy to see the share price up 25% in the last month. But don't... |
SESEN BIO, INC. (SESN) Reports Q3 Loss, Lags Revenue EstimatesSESEN BIO, INC. (SESN) delivered earnings and revenue surprises of 71.43% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? |
SESN Price Returns
| 1-mo | -13.22% |
| 3-mo | 6.37% |
| 6-mo | -71.62% |
| 1-year | -15.32% |
| 3-year | -39.31% |
| 5-year | -50.00% |
| YTD | -22.22% |
| 2020 | 29.81% |
| 2019 | -26.76% |
| 2018 | 75.09% |
| 2017 | -57.54% |
| 2016 | -36.54% |
Loading social stream, please wait...